Thalidomide and lenalidomide: Mechanism-based potential drug combinations

Sonia Vallet; Antonio Palumbo; Noopur Raje; Mario Boccadoro; Kenneth C Anderson

doi:10.1080/10428190802005191

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

Sonia Vallet, Antonio Palumbo, Noopur Raje, Mario Boccadoro, Kenneth C Anderson

Research output: Journal article (peer-reviewed) › Review article

99 Citations (Scopus)

Abstract

Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM). Both drugs reveal a dual mechanism of action: they target tumour cells by direct cytotoxicity and, indirectly, by interfering with several components of the bone marrow microenvironment. Lenalidomide and thalidomide are versatile drugs with a broad range of activities that potentiate the anti-MM effects of conventional and novel agents. Here, we review the mechanism of action of these drugs, providing a rationale for combination studies in order to improve patient outcome and reduce side effects.

Original language	English
Pages (from-to)	1238-1245
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	49
Issue number	7
DOIs	https://doi.org/10.1080/10428190802005191
Publication status	Published - Jul 2008
Externally published	Yes

Keywords

Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Apoptosis/drug effects
Bone Marrow/drug effects
Humans
Immune System/drug effects
Lenalidomide
Multiple Myeloma/drug therapy
Thalidomide/analogs & derivatives

Access to Document

10.1080/10428190802005191

Cite this

@article{ea4b5cde61594f438ff97f10e3bea61e,

title = "Thalidomide and lenalidomide: Mechanism-based potential drug combinations",

abstract = "Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM). Both drugs reveal a dual mechanism of action: they target tumour cells by direct cytotoxicity and, indirectly, by interfering with several components of the bone marrow microenvironment. Lenalidomide and thalidomide are versatile drugs with a broad range of activities that potentiate the anti-MM effects of conventional and novel agents. Here, we review the mechanism of action of these drugs, providing a rationale for combination studies in order to improve patient outcome and reduce side effects.",

keywords = "Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Apoptosis/drug effects, Bone Marrow/drug effects, Humans, Immune System/drug effects, Lenalidomide, Multiple Myeloma/drug therapy, Thalidomide/analogs & derivatives",

author = "Sonia Vallet and Antonio Palumbo and Noopur Raje and Mario Boccadoro and Anderson, {Kenneth C}",

year = "2008",

month = jul,

doi = "10.1080/10428190802005191",

language = "English",

volume = "49",

pages = "1238--1245",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "7",

}

TY - JOUR

T1 - Thalidomide and lenalidomide

T2 - Mechanism-based potential drug combinations

AU - Vallet, Sonia

AU - Palumbo, Antonio

AU - Raje, Noopur

AU - Boccadoro, Mario

AU - Anderson, Kenneth C

PY - 2008/7

Y1 - 2008/7

N2 - Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM). Both drugs reveal a dual mechanism of action: they target tumour cells by direct cytotoxicity and, indirectly, by interfering with several components of the bone marrow microenvironment. Lenalidomide and thalidomide are versatile drugs with a broad range of activities that potentiate the anti-MM effects of conventional and novel agents. Here, we review the mechanism of action of these drugs, providing a rationale for combination studies in order to improve patient outcome and reduce side effects.

AB - Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM). Both drugs reveal a dual mechanism of action: they target tumour cells by direct cytotoxicity and, indirectly, by interfering with several components of the bone marrow microenvironment. Lenalidomide and thalidomide are versatile drugs with a broad range of activities that potentiate the anti-MM effects of conventional and novel agents. Here, we review the mechanism of action of these drugs, providing a rationale for combination studies in order to improve patient outcome and reduce side effects.

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Apoptosis/drug effects

KW - Bone Marrow/drug effects

KW - Humans

KW - Immune System/drug effects

KW - Lenalidomide

KW - Multiple Myeloma/drug therapy

KW - Thalidomide/analogs & derivatives

UR - http://www.scopus.com/inward/record.url?scp=47649085380&partnerID=8YFLogxK

U2 - 10.1080/10428190802005191

DO - 10.1080/10428190802005191

M3 - Review article

C2 - 18452080

SN - 1042-8194

VL - 49

SP - 1238

EP - 1245

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this